FGFR4 Recombinant Monoclonal Antibody

說明書

中文名稱：

FGFR4重組抗體
貨號：

CSB-RA927449A0HU
規格：

￥1320
圖片：
IHC image of CSB-RA927449A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

FGFR4重組單克隆抗體（CSB-RA927449A0HU）是針對成纖維細胞生長因子受體4（FGFR4）開發的高特異性抗體，該靶點屬于酪氨酸激酶受體家族，在細胞信號轉導、組織發育及代謝調控中發揮關鍵作用，尤其在肝臟生物學和病理過程中具有重要研究價值。本產品經嚴格驗證適用于ELISA和免疫組化（IHC）實驗，其中IHC推薦使用1:50至1:200的稀釋范圍，可在石蠟包埋組織切片中清晰呈現FGFR4蛋白的定位與表達水平。實驗數據顯示，該抗體具有優異的批次穩定性和低交叉反應性，可精準識別天然構象的FGFR4抗原表位。其應用場景涵蓋腫瘤機制研究（如肝癌、乳腺癌等FGFR4相關疾病模型）、信號通路解析以及藥物靶點篩選等領域，為探究FGFR4在細胞增殖、分化及代謝異常中的分子機制提供可靠工具。本產品嚴格限定于科學研究用途，不涉及其他應用領域。
Uniprot No.：

P22455
基因名：

FGFR4
別名：

FGFR4; JTK2; TKF; Fibroblast growth factor receptor 4; FGFR-4; CD antigen CD334
反應種屬：

Human
免疫原：

A synthesized peptide derived from human FGFR4
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

8A5
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.
基因功能參考文獻：
1. The FGFR4-388arg variant promotes lung cancer progression by N-cadherin induction. PMID: 29402970
2. These findings suggest that high levels of FGFR4 can increase glucose metabolism and lead to chemoresistance in breast cancer and reveal the mechanistic basis for targeting FGFR4 as a therapeutic opportunity for chemoresistant tumors. PMID: 29763898
3. Taken together, this study provides the first evidence that Blu9931 functions as a FGFR4-selective inhibitor in colorectal cancer (CRC) cells, and Blu9931 may be a new targeted drug. PMID: 29048661
4. Results show that FGFR4 promotes gastric cancer cell proliferation, migration and epithelial-to-mesenchymal transition. Its expression is negatively regulated by miR-491-5p through SNAIL protein. PMID: 29569792
5. Our findings indicate that the FGFR4-388Arg variant may play an important role in lung squamous cell carcinoma, which may be mediated by the overactivation of the MAPK pathway. PMID: 28583379
6. FGFR4 rs351855 could be a novel independent prognostic factor of BCR after radical prostatectomy in the Chinese population. PMID: 27640814
7. This meta-analysis demonstrates the FGFR rs351855 G>A polymorphism is associated with increased cancer risk. PMID: 28445975
8. Our results indicate that mRNA expression of FGFR4-related genes may be a biomarker to define the distinctive molecular phenotype of intrahepatic cholangiocarcinoma PMID: 28445152
9. The present study employed FGFR4 polymorphism to help identify treatments for high risk patients with stage III colon cancer. PMID: 27857023
10. Our data indicate that FGFR4 polymorphic isoforms mediate signaling that yields mitochondrial therapeutic targets of relevance to the actions of different somatostatin analogs. PMID: 27966451
11. In radiosensitive SW480 and DLD1 cells, enforced expression of FGFR4 stabilized RAD51 protein levels resulting in enhanced clearance of gamma-H2AX foci and increased cell survival in the mismatch repair (MMR)-proficient SW480 cells. PMID: 27650548
12. FGFR4/FGF19 autocrine signaling mediates the survival of a subset of basal-like breast cancer cells PMID: 27192118
13. Study shows that loss of FGFR4 expression led to a remarkable increase in sorafenib-induced ROS generation and apoptosis of hepatocellular carcinoma (HCC) cell lines, and demonstrates that hyperactivation of FGF19/FGFR4 signaling in HCC is one of the main mechanisms of sorafenib resistance. PMID: 28069043
14. This is the first study to elucidate FGF19/FGFR4 signaling in favor of hepatocellular carcinoma cells developing from fatty liver PMID: 27447573
15. High expression of FGFR4 is associated with hepatocellular carcinoma. PMID: 26498355
16. Findings show that FGF19 provides a cytoprotective role against ER stress by activating a FGFR4-GSK3beta-Nrf2 signaling cascade, suggesting targeting this signaling node as a candidate therapeutic regimen for hepatocellular carcinoma (HCC) management. PMID: 28951455
17. FGF23 augments pro-fibrotic signalling cascades in injury-primed renal fibroblasts via activation of FGFR4 PMID: 28919046
18. functional clathrin-mediated endocytosis is required for proper FGFR4 signaling PMID: 27615514
19. The frequency of the FGFR4 Arg388 (A) allele was significantly higher in hypertensive subjects (36%) than controls (24.3%). GA,AA, and GA+AA genotypes were significantly associated with risk of hypertension, even after adjusting for age, body mass index, and glucose. Gender stratification showed a significant association only in female subjects. Subjects with GA and AA genotypes showed higher diastolic blood pressure. PMID: 28650667
20. Enhanced myocardial expression of FGFR4 is associated with left ventricular hypertrophy in chronic kidney disease. PMID: 26681731
21. High FGFR4 expression was significantly associated with the depth of invasion, lymph-node metastasis, pathological stage, and distant metastasis or recurrent disease in gastric cancer. PMID: 28056982
22. This study showed that Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors. PMID: 26335532
23. Data suggest that knockdown of fibroblast growth factor receptor 4 (FGFR4) expression might prevent the growth of astric cancer (GC) in vivo. PMID: 26432329
24. FGFR4 is overexpressed in oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC) in the absence of gene amplification, and may serve as a potential predictive marker for FGFR4-directed targeted therapy in OSCC and OPSCC. PMID: 26551585
25. Study shows that FGF19 can be secreted and promotes ovarian cancer progression such as proliferation and invasion by activating FGFR4. PMID: 26323668
26. The FGFR4 single-nucleotide polymorphism rs376618 had borderline significant differences in Patients With Primary Bile Acid Diarrhea. PMID: 26856750
27. Our study provides the first evidence of a role for FGFR4 in neuroblastoma PMID: 26840079
28. KL methylation is a characteristic of many breast cancer cases . However, the resulting or associated perturbation in FGFR4 expression, similar to FGF19, could be utilized as a biomarker for poor prognosis PMID: 26152288
29. The genetic polymorphism in FGFR4 rs351855 may be associated with the risk of HCC coupled with liver cirrhosis and may markedly increase the AFP level PMID: 25860955
30. Using Fgfr4 single nucleotide polymorphism knock-in mice and transgenic mouse models for breast and lung cancers, we validate the enhanced STAT3 signalling induced by the FGFR4 Arg388-variant in vivo PMID: 26675719
31. High tumor expression of FGFR4 protein is not an independent risk factor for gastric cancer initiation, but is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or in the early stages of invasion. PMID: 25684949
32. review summarizes all aspects of FGFR4 physiology and pathophysiology relevant to cacer. PMID: 23944363
33. FGFR4 is an important determinant of the aggressive phenotype of the hepatoma/hepatocarcinoma cell lines. PMID: 25031272
34. The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of FIIN-3 bound with FGFR4 V550L and EGFR L858R. PMID: 25349422
35. Variants in genes involved in feedback regulation of bile acid synthesis (KLB, P=0.06 and FGFR4, P=0.09) were potentially associated with the irritable bowel syndrome-diarrhea subgroup with elevated serum C4. PMID: 25070056
36. The FGFR4 transmembrane polymorphic variants can modulate cellular growth and sensitivity to glucocorticoid hormone negative feedback. PMID: 24625004
37. High FGFR4 expression is associated with drug resistance in alveolar rhabdomyosarcoma. PMID: 24550147
38. In a Chinese population, the FGFR-4 gene polymorphism rs351855G/A was associated with an increased risk for ischemic stroke but was not associated with the ischemic stroke severity or subtype PMID: 24239227
39. FGFR4 silencing markedly reduces the migration and invasion capacity of colorectal cancer cell lines. PMID: 24410190
40. Silencing of FGFR4 reduced cell viability in a panel of colon cancer cell lines and increased caspase-dependent apoptosis. PMID: 24503538
41. The results suggest that proteins, post-translational modifications or mutations that alter structural flexibility of the TKB domain of Cbl-family proteins could regulate their binding to target phosphoproteins and thereby, affect PTK-mediated signalling. PMID: 22888118
42. expression of TGF-beta1 and FGFR4 could make synergy on the occurrence and progression of HCC, and may be used as prognosis indicators for HCC patients PMID: 24324363
43. The genotypes of G388R in FGFR4 gene were in Hardy-Weinberg equilibrium. The percentage of normal homozygotes GG was found to be (48.5%) in breast cancer, (51.8%) in lung cancer. Glycine/arginine was (36.9%) in breast cancer, (42.9%) in lung cancer. PMID: 24416997
44. The single nucleotide polymorphism rs1966265 in FGF receptor 4 is a possible genetic key variant in alveolar diseases of preterm newborns. PMID: 24288432
45. FGFR4 rs351855G/A polymorphism is associated with increased susceptibility to non-Hodgkin's lymphoma (NHL) and could be used as a marker for predicting the prognosis of the malignancy. PMID: 24248544
46. expression of FGFR4 in intrahepatic cholangiocarcinomas, perihilar cholangiocarcinomas and distal cholangiocarcinomas by immunohistochemistry, and association of FGFR4 with clinicopathologic parameters and survival rate PMID: 24565842
47. Inhibition of the activity of FGFR4 may be the main mechanisms of PD effect while 5-Fu reduced FGFR4 expression PMID: 24126887
48. In-depth DNA sequencing identified additional genetic coding and noncoding variants in FGFR4 that are associated with fecal bile acids excretion or colonic transit in Irritable bowel syndrome-diarrhea PMID: 24200957
49. The distribution of FGFR4 AA genotype and A-allele of rs351855G/A was significantly lower in NSCLC patients. PMID: 23524567
50. Suggest that the FGFR4 Gly388Arg polymorphism is not a risk factor for gastric cancer initiation but that it is a useful prognostic marker for GC patients when the tumor is relatively small, well differentiated, or at an early clinical stage. PMID: 23901234
顯示更多

收起更多
相關疾病：

Prostate cancer (PC)
亞細胞定位：

Cell membrane; Single-pass type I membrane protein. Endosome. Endoplasmic reticulum. Note=Internalized from the cell membrane to recycling endosomes, and from there back to the cell membrane.; [Isoform 2]: Secreted.; [Isoform 3]: Cytoplasm.
蛋白家族：

Protein kinase superfamily, Tyr protein kinase family, Fibroblast growth factor receptor subfamily
組織特異性：

Expressed in gastrointestinal epithelial cells, pancreas, and gastric and pancreatic cancer cell lines.
數據庫鏈接：

HGNC: 3691

OMIM: 134935

KEGG: hsa:2264

STRING: 9606.ENSP00000292408

UniGene: Hs.165950

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human